Evotec SE (ETR:EVT - Get Free Report)'s share price was down 0.5% during trading on Wednesday . The company traded as low as €8.72 ($9.18) and last traded at €8.81 ($9.27). Approximately 1,555,984 shares changed hands during mid-day trading, an increase of 14% from the average daily volume of 1,360,000 shares. The stock had previously closed at €8.85 ($9.32).
Evotec Stock Down 2.3 %
The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -9.01, a price-to-earnings-growth ratio of 0.98 and a beta of 1.05. The company has a current ratio of 1.83, a quick ratio of 2.97 and a debt-to-equity ratio of 46.81. The company has a 50-day moving average of €7.64 and a 200-day moving average of €7.65.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
